[Reciprocal priming-boosting role of HBsAg and DNA vaccines].
OBJECTIVE
To evoke more effective humoral and cell-mediated immunization against hepatitis B virus (HBV) infection.


METHODS
HBsAg-primed mice were boosted with HBs-DNA vaccine, and HBs-DNA-primed mice were boosted with HBsAg vaccine. Anti-HBs level was assayed by ELISA and cytotoxic T lymphocyte (CTL) response was tested by lactic acid dehydrogenase (LDH) releasing method two weeks after the boosted immunization.


RESULTS
Anti-HBs level and CTL responsive rate at the effector/target cell ratio of 100:1 were 0.38 and 36% in HBsAg/HBs-DNA vaccination group, 0.32 and 27% in HBs-DNA/HBsAg vaccination group, 0.48 and 1.5% in HBsAg/HBsAg vaccination group, 0.24 and 68% in HBs-DNA/HBs-DNA vaccination group, respectively.


CONCLUSIONS
Priming with HBs-DNA vaccine followed by boosting with conventional HBsAg vaccine results in greater antibody response (F = 21.19, P < 0.05), and CTL response after HBsAg vaccination can be improved by boosting with HBs-DNA vaccine (F = 165.59, P < 0.05). It brings to better efficacy by combining HBsAg vaccine with HBs-DNA vaccine.
Zhou
Zhi
Z
Department of Infectious Diseases, Second Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400010, China.
Chen
Wen-si
WS
Zhang
Hai-hong
HH
Yao
Ji-lu
JL
D000818:Animals; D000917:Antibody Formation; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006515:Hepatitis B virus / Q000235:genetics; D007111:Immunity, Cellular; D051379:Mice; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA